Vaccitech Announces Closing of $110.5 Million Initial Public Offering
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical
company engaged in the discovery and development of novel
immunotherapeutics and vaccines for the treatment and prevention of
infectious diseases and cancer, today announced the closing of its
initial public offering in the United States of 6,500,000 American
Depositary Shares (“ADSs”) representing 6,500,000 ordinary shares
at an initial public offering price of $17.00 per ADS. The gross
proceeds from the offering were approximately $110.5 million.
Vaccitech’s ordinary shares began trading on the Nasdaq Global
Market in the U.S. under the ticker symbol “VACC” on April 30,
2021. All ADSs sold in the offering were offered by Vaccitech.
Morgan Stanley, Jefferies, Barclays and William
Blair acted as joint book-running managers for the offering. H.C.
Wainwright & Co. acted as lead manager for the offering.
The Registration Statement on Form S-1 relating
to the proposed sale of these securities was filed with the U.S.
Securities and Exchange Commission and was declared effective on
April 29, 2021.
The offering of ADSs was made only by means of a
prospectus, copies of which may be obtained from: Morgan Stanley
& Co. LLC, Attention: Prospectus Department, 180 Varick Street,
2nd Floor, New York, NY 10014, or by email at
email@example.com; Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd
Floor, New York, NY 10022, by telephone at (877) 821-7388
or by email at firstname.lastname@example.org; Barclays
Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717 or by email
at email@example.com or telephone at
1-888-603-5847; or William Blair & Company, L.L.C., Attention:
Prospectus Department, 150 North Riverside Plaza, Chicago,
IL 60606, by telephone at (800) 621-0687, or by
email at firstname.lastname@example.org.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of any securities in any state or
jurisdiction in which such offer, solicitation, or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Vaccitech plcVaccitech is
a clinical-stage biopharmaceutical company engaged in the discovery
and development of novel immunotherapeutics and vaccines for the
treatment and prevention of infectious diseases and cancer. The
company’s proprietary platform comprises proprietary modified
simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as
the well-validated Modified Vaccinia Ankara, or MVA, boost vector,
both with demonstrable tolerability profiles and without the
ability to replicate in humans. The combination of a ChAdOx prime
treatment with subsequent MVA boost has consistently generated
significantly higher magnitudes of CD8+ T cells compared with other
technologies and approaches. The company has a broad pipeline of
both clinical and preclinical stage therapeutic programs in solid
tumors and viral infections and prophylactic viral vaccine
programs. Vaccitech co-invented a COVID-19 vaccine with the
University of Oxford, now approved for use in many territories and
exclusively licensed worldwide to AstraZeneca through Oxford
University Innovation, or OUI. Vaccitech is entitled to receive a
share of the milestones and royalty income received by OUI from
Vaccitech Media contacts:Katja Stout, Scius
Communications (EU)Direct: +44 (0)
Ryo Imai / Robert Flamm, Ph.D. (US), Burns McClellan,
Inc.212-213-0006 ext. 315 / 364Email: email@example.com
Henry Hodge, VaccitechDirect: +44 (0) 7533 421